News & Events

News Releases

Date Title and Summary
Toggle Summary Leading Cancer Research Centers Team up to Launch Biotech Startup Focused on Cancer Immunotherapy
Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute join together to launch Juno Therapeutics Inc. Company founded with $120M initial investment, among largest fully committed Series A for a biotech startup in
Toggle Summary Juno Announces New Investments, Leadership Appointments
SEATTLE, Jan. 13, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, a new biotechnology company focused on bringing forward novel immunotherapies for cancer, announced today an expanded Series A including Bezos Expeditions, the personal investment company of Jeff Bezos, and leading venture capital
Toggle Summary Juno Therapeutics Appoints Biotech Investment Banking Leader Steve Harr as CFO and Head of Corporate Development
SEATTLE , March 31, 2014 /PRNewswire/ -- Juno Therapeutics, a biotechnology company focused on bringing forward novel immunotherapies for cancer, announced today that Steve Harr , M.D., will join the company as its Chief Financial Officer and Head of Corporate Development.
Toggle Summary Juno Completes $176M Series A Round
SEATTLE , April 24, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, a biotechnology company focused on bringing forward novel immunotherapies for cancer, today announced the close of its Series A round with $176M in fully committed funds. Juno's initial funding of $120 million came predominantly
Toggle Summary Juno Scientific Founders Receive NYIPLA Inventor of the Year Award
Drs. Michel Sadelain, Renier J. Brentjens of Memorial Sloan Kettering Cancer Center recognized for CARs research Juno Therapeutics, a biotechnology company focused on bringing forward novel immunotherapies for cancer, today congratulated two of its scientific founders, Drs.
Toggle Summary Juno Therapeutics today announced the close of its B round of financing with $134M in new investment
Total investment in the company now tops $300M in less than 12 Months Juno Therapeutics, Inc., a biotechnology company focused on bringing forward novel immunotherapies for cancer, today announced that it has closed its Series B round with $134M in new investment.
Toggle Summary Juno Appoints Hal Barron, M.D. to Board of Directors
Juno Therapeutics, Inc. today announced the appointment of Hal Barron, M.D., President of Research & Development at Calico, to its Board of Directors “Hal is one of the most respected clinician-scientists and successful drug developers in the biotechnology industry.
Toggle Summary Juno Therapeutics Files Registration Statement For Initial Public Offering
Seattle, Washington, November 17, 2014 /PRNewswire/ — Juno Therapeutics, Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission relating to a proposed initial public offering of its common stock.
Toggle Summary Juno's JCAR015 Leukemia T Cell Therapy Granted Orphan Drug Designation By FDA
SEATTLE , Nov. 18, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, Inc. announced today that the FDA has granted Orphan Drug Designation to its JCAR015 chimeric antigen receptor product candidate. The designation was granted for treatment of acute lymphoblastic leukemia.
Toggle Summary Juno T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation
SEATTLE , Nov. 24, 2014 /PRNewswire/ -- Juno Therapeutics today announced that the FDA has granted Breakthrough Therapy Designation to the company's JCAR015 chimeric antigen receptor product candidate. The designation applies for the treatment of relapsed or refractory B-cell acute lymphoblastic